LivingGLP1
Study S001057

A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects

Registration

Registration
NCT03841630
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
DOUBLE
Status
COMPLETED
Enrollment
45
Start
2019-03-13
Primary completion
2019-07-25
Lead sponsor
Eli Lilly and Company
Conditions
Healthy
Interventions
DRUG:LY3437943; DRUG:Placebo
Results posted
FALSE
Individual participant data sharing
NO
Secondary identifiers
OTHER:J1I-MC-GZBA

Registered primary outcomes

  • Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through final follow-up at approximately Day 43]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.